Business
Fresenius Kabi to announce the commercial launch of Otulfi™*, an approved Ustekinumab Biosimilar in Canada
Fresenius Kabi Canada announces that its ustekinumab biosimilar, developed by Formycon AG, is now commercially available in Canada. Otulfi™ is indicated for the treatment of several serious inflammatory diseases and benefiting more patients with autoimmune conditions. It is the third Fresenius Kabi immunology biosimilar approved in Canada for the treatment of Gastroenterology, Dermatology or Rheumatology conditions, providing treatment flexibility to manage patients at different stages of their
About this update from Formycon Ag
[{"type":"list","items":[{"val":[{"type":"text","content":"Fresenius Kabi's ustekinumab biosimilar Otulfi™ is now commercially available for both subcutaneous and intravenous formulations","length":132,"tagName":"p"}]},{"val":[{"type":"text","content":"With this launch, Fresenius Kabi Canada's immunology biosimilar portfolio is further expanding, offering more treatment options for patients with chronic autoimmune conditions","length":179,"tagName":"p"}]},{"val":[{"type":"text","content":"Otulfi™ is available for adult patients with moderate to severe active Crohn's disease, moderate to severe active ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis indications, consistent with the adult indications of the originator biologic Stelara®**","length":298,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":609,"olType":false},{"type":"text","content":"TORONTO, May 27, 2025 /CNW/ - Fresenius Kabi Canada announces that its ustekinumab biosimilar, developed by Formycon AG, is now commercially available in Canada. Otulfi™ is indicated for the treatment of several serious inflammatory diseases and benefiting more patients with autoimmune conditions. It is the third Fresenius Kabi immunology biosimilar approved in Canada for the treatment of Gastroenterology, Dermatology or Rheumatology conditions, providing treatment flexibility to manage patients at different stages of their autoimmune conditions. The Otulfi™ launch milestone represents the third product launch within a span of less than two months, featuring the introduction of Idacio® (adalimumab) Citrate-free formulation and the launch of Tyenne® (tocilizumab).","length":778,"tagName":"p"},{"type":"image","alt":"Logo de Fresenius Kabi (CNW Group/Fresenius Kabi Canada Inc.)","displaySize":"","headline":null,"caption":"Logo de Fresenius Kabi (CNW Group/Fresenius Kabi Canada Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":207,"height":62,"url":"https://media.zenfs.com/en/cnwgroup.com/c55c612a6ed02a146b07e0a6ef2095a4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1xYZ9wMpdqGQFkH_vk__Sg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEwODtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/c55c612a6ed02a146b07e0a6ef2095a4","width":207,"height":62}},"href":"https://mma.prnewswire.com/media/2696136/Fresenius_Kabi_Canada_Inc__Fr...